Hormone Replacement Therapy in Relation to Risk of Cataract Extraction. A Prospective Study of Women

Ophthalmology

Volumn 117, Issue 3, 2010, Pages 424-430

  Lindblad, Birgitta Ejdervik ^a,b   Håkansson, Niclas ^a   Philipson, Bo ^c   Wolk, Alicja ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SUNDSVALL HOSPITAL   (Sweden)

^c Sophiahemmet Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CATARACT EXTRACTION; COHORT ANALYSIS; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LIFESTYLE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SMOKING; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; CATARACT; CATARACT EXTRACTION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SMOKING; SWEDEN; WOMEN'S HEALTH;

EID: 77049085480     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.07.046     Document Type: Article

References (61)

1. Sperduto R.D., and Hiller R. The prevalence of nuclear, cortical, and posterior subcapsular lens opacities in a general population sample. Ophthalmology 91 (1984) 815-818
2. Leske M.C., Wu S.Y., Nemesure B., et al., Barbados Eye Studies Group. Nine-year incidence of lens opacities in the Barbados Eye Studies. Ophthalmology 111 (2004) 483-490
3. Mitchell P., Cumming R.G., Attebo K., and Panchapakesan J. Prevalence of cataract in Australia: the Blue Mountains Eye Study. Ophthalmology 104 (1997) 581-588
4. Klein B.E., Klein R., and Linton K.L. Prevalence of age-related lens opacities in a population: the Beaver Dam Eye Study. Ophthalmology 99 (1992) 546-552
5. Delcourt C., Cristol J.P., Tessier F., et al., POLA Study Group. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: the POLA study. Am J Epidemiol 151 (2000) 497-504
6. McCarty C.A., Mukesh B.N., Fu C.L., and Taylor H.R. The epidemiology of cataract in Australia. Am J Ophthalmol 128 (1999) 446-465
7. Ostberg A., Löth A., Gustafson D., and Lindblom B. Skövde cataract study: I. Prevalence of lens opacities in a Swedish community. Ophthalmology 113 (2006) 970-975
8. Nelson H.D., Humphrey L.L., Nygren P., et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 (2002) 872-881
9. Klein B.E. Lens opacities in women in Beaver Dam, Wisconsin: is there evidence of an effect of sex hormones?. Trans Am Ophthalmol Soc 91 (1993) 517-544
10. Freeman E.E., Munoz B., Schein O.D., and West S.K. Hormone replacement therapy and lens opacities: the Salisbury Eye Evaluation project. Arch Ophthalmol 119 (2001) 1687-1692
11. Cumming R.G., and Mitchell P. Hormone replacement therapy, reproductive factors, and cataract: the Blue Mountains Eye Study. Am J Epidemiol 145 (1997) 242-249
12. Klein B.E., Klein R., and Lee K.E. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the Beaver Dam Eye Study. Am J Ophthalmol 130 (2000) 322-326
13. Freeman E.E., Munoz B., Schein O.D., and West S.K. Incidence and progression of lens opacities: effect of hormone replacement therapy and reproductive factors. Epidemiology 15 (2004) 451-457
14. Younan C., Mitchell P., Cumming R.G., et al. Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol 155 (2002) 997-1006
15. Defay R., Pinchinat S., Lumbroso S., et al., POLA Study Group. Relationships between hormonal status and cataract in French postmenopausal women: the POLA Study. Ann Epidemiol 13 (2003) 638-644
16. Weintraub J.M., Taylor A., Jacques P., et al. Postmenopausal hormone use and lens opacities. Ophthalmic Epidemiol 9 (2002) 179-190
17. Worzala K., Hiller R., Sperduto R.D., et al. Postmenopausal estrogen use, type of menopause, and lens opacities: the Framingham studies. Arch Intern Med 161 (2001) 1448-1454
18. Lindblad B.E., Hakansson N., Svensson H., et al. Intensity of smoking and smoking cessation in relation to risk of cataract extraction: a prospective study of women. Am J Epidemiol 162 (2005) 73-79
19. Colditz G.A., Stampfer M.J., Willett W.C., et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 126 (1987) 319-325
20. Banks E., Beral V., Cameron R., et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 6 (2001) 357-363
21. Lundström M., Stenevi U., and Thorburn W. The Swedish National Cataract Register: a 9-year review. Acta Ophthalmol Scand 80 (2002) 248-257
22. Colenbrander A. Preservation of vision or prevention of blindness?. Am J Ophthalmol 133 (2002) 263-265
23. Cox D.R. Regression models and life-tables. J R Statist Soc Series B 34 (1972) 187-220
24. Aina F.O., Smeeth L., Hubbard R., et al. Hormone replacement therapy and cataract: a population-based case-control study. Eye 20 (2006) 417-422
25. Lumb G., Mitchell L., and de la Iglesia F.A. Regression of pathologic changes induced by the long-term administration of contraceptive steroids to rodents. Toxicol Pathol 13 (1985) 283-295
26. Hales A.M., Chamberlain C.G., Murphy C.R., and McAvoy J.W. Estrogen protects lenses against cataract induced by transforming growth factor-beta (TGFbeta). J Exp Med 185 (1997) 273-280
27. Bigsby R.M., Cardenas H., Caperell-Grant A., and Grubbs C.J. Protective effects of estrogen in a rat model of age-related cataracts. Proc Natl Acad Sci U S A 96 (1999) 9328-9332
28. Keating N.L., Cleary P.D., Rossi A.S., et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 130 (1999) 545-553
29. Li C., Samsioe G., Lidfelt J., et al. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study. Menopause 7 (2000) 273-281
30. Bergkvist L., Bixo M., Bjorkelund D., et al. Summary and conclusions of the SBU report on hormone replacement therapy: an evidence based review. Gustafson R, trans. (2002), Swedish Council on Technology Assessment in Health Care, Stockholm 27-33. http://www.sbu.se/upload/Publikationer/Content0/1/ostrogen_2002/ostrogen_eng.pdf Assessed May 28, 2009
31. Brett K.M., and Madans J.H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 145 (1997) 536-545
32. Bjørnerem A., Straume B., Midtby M., et al. Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromsø Study. J Clin Endocrinol Metab 89 (2004) 6039-6047
33. Ogueta S.B., Schwartz S.D., Yamashita C.K., and Farber D.B. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci 40 (1999) 1906-1911
34. Wickham L.A., Gao J., Toda I., et al. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand 78 (2000) 146-153
35. Niki E., and Nakano M. Estrogens as antioxidants. Methods Enzymol 186 (1990) 330-333
36. Mooradian A.D. Antioxidant properties of steroids. J Steroid Biochem Mol Biol 45 (1993) 509-511
37. Paganini-Hill A., and Clark L.J. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60 (2000) 167-172
38. Wang X., Simpkins J.W., Dykens J.A., and Cammarata P.R. Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci 44 (2003) 2067-2075
39. Samadi A., Carlson C.G., Gueorguiev A., and Cenedella R.J. Rapid, non-genomic actions of progesterone and estradiol on steady-state calcium and resting calcium influx in lens epithelial cells. Pflugers Arch 444 (2002) 700-709
40. Truscott R.J., Marcantonio J.M., Tomlinson J., and Duncan G. Calcium-induced opacification and proteolysis in the intact rat lens. Invest Ophthalmol Vis Sci 31 (1990) 2405-2411
41. Jedziniak J.A., Kinoshita J.H., Yates E.M., et al. Calcium-induced aggregation of bovine lens alpha crystallins. Invest Ophthalmol 11 (1972) 905-915
42. Dilsiz N., Olcucu A., and Atas M. Determination of calcium, sodium, potassium and magnesium concentrations in human senile cataractous lenses. Cell Biochem Funct 18 (2000) 259-262
43. Lowe G.D., Upton M.N., Rumley A., et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey. Thromb Haemost 86 (2001) 550-556
44. Lacut K., Oger E., Le Gal G., et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 90 (2003) 124-131
45. Fröhlich M., Mühlberger N., Hanke H., et al. Markers of inflammation in women on different hormone replacement therapies. Ann Med 35 (2003) 353-361
46. Cooper B.C., Burger N.Z., Toth M.J., et al. Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. [report online]. Am J Obstet Gynecol 196 (2007). 123e1-7 http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=17306648 Accessed August 8, 2009
47. de Maat M.P., Madsen J.S., Langdahl B., et al. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thromb Haemost 97 (2007) 234-239
48. Ridker P.M., Hennekens C.H., Rifai N., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
49. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100 (1999) 717-722
50. Cushman M., Meilahn E.N., Psaty B.M., et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19 (1999) 893-899
51. Silvestri A., Gebara O., Vitale C., et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 107 (2003) 3165-3169
52. Klein B.E., Klein R., Lee K.E., et al. Markers of inflammation, vascular endothelial dysfunction, and age-related cataract. Am J Ophthalmol 141 (2006) 116-122
53. Schaumberg D.A., Ridker P.M., Glynn R.J., et al. High levels of plasma C-reactive protein and future risk of age-related cataract. Ann Epidemiol 9 (1999) 166-171
54. Hankinson S.E., Willett W.C., Manson J.E., et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87 (1995) 1297-1302
55. Gavaler J.S., and Van Thiel D.H. The association between moderate alcoholic beverage consumption and serum estradiol and testosterone levels in normal postmenopausal women: relationship to the literature. Alcohol Clin Exp Res 16 (1992) 87-92
56. Dorgan J.F., Baer D.J., Albert P.S., et al. Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst 93 (2001) 710-715
57. Ginsburg E.S., Walsh B.W., Shea B.F., et al. The effects of ethanol on the clearance of estradiol in postmenopausal women. Fertil Steril 63 (1995) 1227-1230
58. Ginsburg E.S., Mello N.K., Mendelson J.H., et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 276 (1996) 1747-1751
59. Thunell L., Stadberg E., Milsom I., and Mattsson L.A. Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstet Gynecol Scand 84 (2005) 395-401
60. Rothman K.J., and Greenland S. Modern Epidemiology. 2nd ed. (1998), Lippincott-Raven, Philadelphia 115-134
61. Javitt J.C., and Taylor H.R. Cataract and latitude. Doc Ophthalmol 88 (1994) 307-325